PROTO SCRIPT PHARMACEUTICAL CORP Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues
PROTO SCRIPT PHARMACEUTICAL CORP reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues of $664.42 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-03-08.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues · last filed 2018-03-08
- PROTO SCRIPT PHARMACEUTICAL CORP fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for the quarter ending 2017-09-30 was -$1.00.
- PROTO SCRIPT PHARMACEUTICAL CORP fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for the quarter ending 2017-06-30 was $0.00.
- PROTO SCRIPT PHARMACEUTICAL CORP fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for the quarter ending 2017-03-31 was $664.42K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 9 month |
|---|---|---|---|
| 2017-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-08 | -$1.00 derived: sum of 2 quarters · filed 2018-03-08 | $664.42K 10-Q · filed 2018-03-08 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-01-17 | $664.42K 10-Q · filed 2018-01-17 | |
| 2017-03-31 | $664.42K 10-Q · filed 2017-11-22 |